Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation

Share-based compensation

3 Months Ended

Mar. 31, 2024

Note 11 — Share-based compensation

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):


		Three months ended
		March 31,
	2024		2023
Research and development	$	813	$	116
General and administrative		2,289		1,560
	$	3,102	$	1,676

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:


		Three months ended
		March 31,
	2024		2023
Number of options over ordinary shares granted		37,097,688		21,755,328
Weighted average fair value of ordinary shares options	$	0.12	$	0.25
Number of additional options with a nominal exercise price granted		26,984,352		19,866,912
Weighted average fair value of options with a nominal exercise price	$	0.14	$	0.32